title: Benefit-risk assessment of diacerein in the treatment of osteoarthritis.
abstract: Osteoarthritis (OA) is the leading musculoskeletal cause of disability. Despite this, there is no consensus on the precise definition of OA and what is the best treatment to improve symptoms and slow disease progression. Current pharmacological treatments include analgesics, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase (COX) inhibitors. None of those treatments are disease-modifying agents that target the core pathological processes in OA. Diacerein, a semi-synthetic anthraquinone derivative, inhibits the interleukin-1-beta (IL-1β) cytokine which, according to animal studies, plays a key role in the pathogenesis of OA. Diacerein was synthesized in 1980 and licensed in some European Union and Asian countries for up to 20 years. It has shown modest efficacy and acceptable tolerability in a number of trials of low to moderate quality. Early this year, the European Medicines Agency (EMA) conducted a review and restricted the use of diacerein-containing medicines. This was because of major concerns about the frequency and severity of diarrhoea and liver disorders in OA patients. In addition, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) questioned the limited clinical benefits of diacerein, which, in their view, did not outweigh its risks. The aim of this review is to provide a benefit-risk assessment of diacerein in the treatment of OA, based on asystematic evaluation of the published efficacy and safety data. Overall, there is evidence that diacerein is modestly effective for symptoms and possibly for radiographic changes, but this needs to be balanced against higher rates of gastrointestinal toxicity.
authors: Menzies Research Institute, Private Bag 23, Hobart, TAS, 7000, Australia.
authors: Elena
authors: E
authors: Panova
authors: Graeme
authors: G
authors: Jones
mesh_terms: D000880:Anthraquinones / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D003967:Diarrhea / Q000139:chemically induced; D006801:Humans; D010003:Osteoarthritis / Q000000981:diagnostic imaging / Q000188:drug therapy; D011859:Radiography; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000880:Anthraquinones; D000893:Anti-Inflammatory Agents; C025292:diacerein
references: Arthritis Rheum. 2000 Oct;43(10):2339-48
references: 11037895
references: Osteoarthritis Cartilage. 2011 May;19(5):478-82
references: 21396464
references: Ann Rheum Dis. 1991 Jun;50(6):395-400
references: 2059083
references: Osteoarthritis Cartilage. 2007 Jun;15(6):605-14
references: 17448700
references: Arthritis Rheum. 2007 Dec;56(12):4055-64
references: 18050202
references: Osteoarthritis Cartilage. 2010 Apr;18(4):476-99
references: 20170770
references: Ann Rheum Dis. 2004 Dec;63(12):1611-7
references: 15331394
references: Arthritis Rheum. 2001 Nov;44(11):2539-47
references: 11710710
references: Drugs. 1997 Jan;53(1):98-106; discussion 107-8
references: 9010651
references: Cochrane Database Syst Rev. 2014 Feb 10;(2):CD005117
references: 24515444
references: Osteoarthritis Cartilage. 2010 Nov;18(11):1441-7
references: 20816981